🔓 Unlock the full profile of Shanmugam Muthusamy (Saimirra Innopharm Private Limited), including verified contact details, financial insights, and professional associations.
See Shanmugam Muthusamy Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: sha*****@sai******.com
Mobile: 88112*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- Muthusamy Shanmugam has held significant positions in the pharmaceutical industry, currently serving as the Director & Head of Research & Development at ANI Pharmaceuticals, Inc. since 2021.
- Shanmugam's leadership extends to roles as Director at Saimirra Innopharm Pvt Ltd, where a focus on innovative pharmaceutical solutions has been a priority since joining in 2012.
- In addition to Saimirra Innopharm, Shanmugam has been a director at Sthree Pharmaceuticals Private Limited since 2017, contributing to the growth and development of the organization.
- Holding a Director Identification Number (DIN) of 02684873, Muthusamy Shanmugam is recognized in various corporate registrations, which include multiple pharmaceutical firms such as Scitus Pharma Services Private Limited.
- Shanmugam's expertise in research and development has had a profound impact on enhancing product portfolios, supporting regulatory compliance, and driving innovation within the pharmaceutical sector.
- By building and maintaining strong networks within the industry, Shanmugam has established connections that facilitate collaboration and knowledge sharing among peers and professionals.
- Challenges faced include navigating the complex regulatory landscape of the pharmaceutical industry, requiring strategic planning and robust R&D methodologies to ensure successful product development.
- Muthusamy Shanmugam's strategic contributions have positioned organizations to adapt to evolving market needs, ensuring a competitive edge in a rapidly changing industry.
| CIN/LLP | Company Name | Designation | Appointment Date |
|---|---|---|---|
| AAE-4532 | Annamar Pharma Llp | Designated Partner | 22 Sep 2017 |
| U24100TN2009PTC072376 | Delvin Formulations Private Limited | Director | 24 Jul 2009 |
| U24110TN2012PTC086320 | Nuray Chemicals Private Limited | Director | 20 Jul 2016 |
| U24232TN2000PTC044315 | Saimirra Innopharm Private Limited | Director | 22 Oct 2012 |
| U24290TN2022PTC155725 | Esjay Pharma Private Limited | Additional Director | 30 Jul 2024 |
| U24297TN2015PTC101802 | Sthree Pharmaceuticals Private Limited | Director | 06 Oct 2017 |
| U24299TN2020PTC140109 | Sthree Chemicals Private Limited | Director | 10 Aug 2022 |
| U40106TN2022PTC149069 | Samy Solar Private Limited | Director | 07 Jan 2022 |
| U74999TN2016PTC112516 | Novitium Labs Private Limited | Director | 15 Sep 2016 |
| U74999TN2017PTC118805 | Scitus Pharma Services Private Limited | Director | 26 Sep 2017 |
| CIN/LLP | Company Name | Designation | Appointment Date | End Date |
|---|---|---|---|
| U33111TN1982PTC009602 | Par Formulations Private Limited | Director | 29 Jun 2009| 17 February 2012 |